Who owns Y21089191 - DR REDDYS LABORATORIES LTD - Common Stock based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

DR REDDYS LABORATORIES LTD - Common Stock Institutional Ownership

Q: What is CUSIP Y21089191?

CUSIP Y21089191 is the security identifier used in SEC filing datasets for Y21089191 - DR REDDYS LABORATORIES LTD - Common Stock.

CUSIP: Y21089191

13F Institutional Holders and Ownership History from Q4 2024 to Q1 2025

Type / Class: Equity / Common Stock
Shares outstanding: 842,312,512

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP Y21089191?
CUSIP Y21089191 identifies Y21089191 - DR REDDYS LABORATORIES LTD - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP Y21089191:

Q1 2025 (0 holders) Q4 2024 (1 holder)

Significant Owners of DR REDDYS LABORATORIES LTD - Common Stock based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
BlackRock, Inc.	4.1%				34,534,813		BlackRock, Inc.	31 Mar 2025

Institutional Holders of DR REDDYS LABORATORIES LTD - Common Stock across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q1	0	$0	-$33,203,000				0
2024 Q4	2,053,475	$33,203,000	+$33,203,000			$16.17	1